Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

Bibliographic Details
Title: Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial
Authors: Bear, Harry D, Tang, Gong, Rastogi, Priya, Geyer, Charles E, Jr, Liu, Qing, Robidoux, André, Baez-Diaz, Luis, Brufsky, Adam M, Mehta, Rita S, Fehrenbacher, Louis, Young, James A, Senecal, Francis M, Gaur, Rakesh, Margolese, Richard G, Adams, Paul T, Gross, Howard M, Costantino, Joseph P, Paik, Soonmyung, Swain, Sandra M, Mamounas, Eleftherios P, Wolmark, Norman
Source: In The Lancet Oncology September 2015 16(9):1037-1048
Database: ScienceDirect
More Details
ISSN:14702045
DOI:10.1016/S1470-2045(15)00041-8
Published in:The Lancet Oncology
Language:English